tm logo
EARLI
Live/Registered
REGISTERED

on 14 Mar 2023

Last Applicant/ Owned by

801 California Street

Mountain View

CA

94022

Serial Number

88020634 filed on 29th Jun 2018

Registration Number

7000700 registered on 14th Mar 2023

in the Principal Register

Correspondent Address

Connie L. Ellerbach

FENWICK & WEST LLP

801 CALIFORNIA STREET

MOUNTAIN VIEW, CA 94041

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

EARLI

Assays, recombinant nucleic acid vectors, transfection agents, reagents, enzymes, and nucleotides for clinical or medical laboratory, scientific, or research purposes; diagnostic or screening assays or agents, reagents, enzymes, and nucleotides for clinical or medical laboratory, scientific, and research, purposes; reagents for medical and genetic research; chemical reagents and diagnostic preparaRead More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical and veterinary preparations and products for the prevention, detection, localization, and treatment of cancer, respiratory diseases, and liver diseases; Drug delivery agents in the form of compounds that facilitate the delivery of other pharmaceutical products into human and animal bodies; clinical medical diagnostic or therapeutic reagents and clinical diagnostic kits comprised of clinical medical diagnostic or therapeutic reagents; medical diagnostic or therapeutic reagents and medical diagnostic or therapeutic kits comprised of medical diagnostic or therapeutic reagents; reagents for medical use and medical diagnostics or therapeutics and screening kits comprised of reagents for medical diagnostics and screening use or therapeutics; reagents for use in testing for medical and medical diagnostic purposes; diagnostic and therapeutic preparations for medical purposes, namely, to detect and treat cancer, respiratory diseases, and liver diseases; diagnostic or therapeutic assays, vectors, reagents, enzymes, and nucleotides for medical or clinical purposes; diagnostic or screening assays, reagents, enzymes, and nucleotides for medical diagnostic purposes and treatment purposes, namely, to detect and treat cancer, respiratory diseases, and liver diseases; reagents for medical diagnostic purposes and treatment use; therapeutic agents for medical diagnostic purposes and treatment, namely, viral vectors and non-viral transfection agents based on linear or branched polyethylenimines, nanoparticles, lipophilic particles, peptides, micelles, dendrimers, hydrogels, synthetic or naturally derived exosomes, polymeric composition, or virus-like particles, which facilitate the delivery of pharmaceuticals or nucleic acids into human and animal bodies to detect and treat cancer, respiratory diseases, and liver diseases


First Use Date in General

18th Jan 2023

First Use Date in Commerce

18th Jan 2023

Class [001]
Chemical Products


Assays, recombinant nucleic acid vectors, transfection agents, reagents, enzymes, and nucleotides for clinical or medical laboratory, scientific, or research purposes; diagnostic or screening assays or agents, reagents, enzymes, and nucleotides for clinical or medical laboratory, scientific, and research, purposes; reagents for medical and genetic research; chemical reagents and diagnostic preparations for clinical or medical laboratory use


First Use Date in General

18th Jan 2023

First Use Date in Commerce

18th Jan 2023

Mark Details


Serial Number

No 88020634

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 34601-00070

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
14th Mar 2023REGISTERED-PRINCIPAL REGISTER
14th Mar 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
10th Feb 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09th Feb 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02th Feb 2023STATEMENT OF USE PROCESSING COMPLETE
31st Jan 2023TEAS STATEMENT OF USE RECEIVED
31st Jan 2023USE AMENDMENT FILED
18th Jan 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17th Jan 2023SOU EXTENSION 5 GRANTED
04th Jan 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL